TESARO Company Profile (NASDAQ:TSRO)

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

TESARO, Inc. (NASDAQ:TSRO) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by $0.30. The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm's quarterly revenue was down 17.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.28) earnings per share. View TESARO's Earnings History.

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for TESARO.

22 brokerages have issued 1 year price targets for TESARO's shares. Their forecasts range from $120.00 to $236.00. On average, they expect TESARO's share price to reach $169.82 in the next year. View Analyst Ratings for TESARO.

Here are some recent quotes from research analysts about TESARO stock:

• 1. Cann analysts commented, "These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease." (9/8/2017)
• 2. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
• 3. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
• 4. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)
• 5. Robert W. Baird analysts commented, "Earlier today, SOLO-2 data were presented at the SGO meeting, indicating AstraZeneca's Lynparza is comparable to Tesaro's niraparib in 2L+ ovarian cancer maintenance. Though only in gBRCA patients, these data suggest differences in efficacy among PARP's may be minimal. Next up is data from Clovis' Rubraca (ARIEL-3) in mid-2017, which will provide greater clarity on PARP competition in the non-gBRCA ovarian population. As we highlighted, with the PARP space shaping up to be less differentiated than initially thought, we reiterate our Neutral rating." (3/15/2017)

TESARO saw a decline in short interest during the month of September. As of September 29th, there was short interest totalling 6,767,191 shares, a decline of 28.5% from the September 15th total of 9,459,637 shares. Based on an average daily trading volume, of 570,698 shares, the days-to-cover ratio is presently 11.9 days. Approximately 17.9% of the company's stock are sold short.

Some companies that are related to TESARO include Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA) and Ultragenyx Pharmaceutical (RARE).

TESARO's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
• Leon O. Moulder Jr., Chief Executive Officer, Director
• Timothy R. Pearson, Chief Financial Officer, Executive Vice President
• Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
• Grant C. Bogle, Senior Vice President, Chief Commercial Officer
• Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
• Lawrence M. Alleva, Independent Director
• James O. Armitage M.D., Independent Director

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TESARO stock can currently be purchased for approximately $120.31.